共 178 条
[1]
Hu-Lowe DD(2008)Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 7272-7283
[2]
Zou HY(2010)Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers Cancer Chemother Pharmacol 65 563-570
[3]
Grazzini ML(2007)Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 975-984
[4]
Hallin ME(2008)Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study J Clin Oncol 26 4708-4713
[5]
Wickman GR(2009)Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study J Clin Oncol 27 3836-3841
[6]
Amundson K(2005)Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474-5483
[7]
Chen JH(2012)Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers Invest New Drugs 30 273-281
[8]
Rewolinski DA(2003)CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 176-181
[9]
Yamazaki S(1999)Effects of food on clinical pharmacokinetics Clin Pharmacokinet 37 213-255
[10]
Wu EY(2008)Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients Anticancer Drugs 19 275-281